(±)-AMG 487 - CAS 473719-41-4
Catalog number: 473719-41-4
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C32H28F3N5O4
Molecular Weight:
603.59
COA:
Inquire
Targets:
CXCR
Description:
CXCR3 antagonist; Inhibits cell migration and metastasis
Brife Description:
CXCR3 antagonist; Inhibits cell migration and metastasis
Appearance:
Solid powder
Synonyms:
AMG-487; AMG 487; AMG487. Benzeneacetamide, N-((1R)-1-(3-(4-ethoxyphenyl)-3,4-dihydro-4-oxopyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(3-pyridinylmethyl)-4-(trifluoromethoxy)-; N-[(1R)-1-[3-(4-ethoxyphenyl)-4-oxopyrido[2,3-d]pyrimidin-2-yl]ethyl]-N-(pyridin-3-ylmethyl)-2-[4-(trifluorome
Solubility:
Soluble to 100 mM in DMSO
Storage:
Store at -20°C
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Milligrams-Grams
Melting Point:
161.2℃ (ethyl acetate heptane )
InChIKey:
WQTKNBPCJKRYPA-OAQYLSRUSA-N
InChI:
1S/C32H28F3N5O4/c1-3-43-25-14-10-24(11-15-25)40-30(38-29-27(31(40)42)7-5-17-37-29)21(2)39(20-23-6-4-16-36-19-23)28(41)18-22-8-12-26(13-9-22)44-32(33,34)35/h4-17,19,21H,3,18,20H2,1-2H3/t21-/m1/s1
Canonical SMILES:
CCOc1ccc(cc1)n2c(=O)c3cccnc3nc2[C@@H](C)N(Cc4cccnc4)C(=O)Cc5ccc(cc5)OC(F)(F)F
1.An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.
Tonn GR1, Wong SG, Wong SC, Johnson MG, Ma J, Cho R, Floren LC, Kersey K, Berry K, Marcus AP, Wang X, Van Lengerich B, Medina JC, Pearson PG, Wong BK. Drug Metab Dispos. 2009 Mar;37(3):502-13. doi: 10.1124/dmd.108.021931. Epub 2008 Dec 16.
(R)-N-{1-[3-(4-Ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]-pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxyphenyl)-acetamide (AMG 487) is a potent and selective orally bioavailable chemokine (C-X-C motif) receptor 3 (CXCR3) antagonist that displays dose- and time-dependent pharmacokinetics in human subjects after multiple oral dosing. Although AMG 487 exhibited linear pharmacokinetics on both days 1 and 7 at the 25-mg dose, dose- and time-dependent kinetics were evident at the two higher doses. Nonlinear kinetics were more pronounced after multiple dosing. Area under the plasma concentration-time curve from 0 to 24 h [AUC((0-24 h))] increased 96-fold with a 10-fold increase in dose on day 7 compared with a 28-fold increase in AUC((0-24 h)) on day 1. These changes were correlated with time- and dose-dependent decreases in the metabolite to parent plasma concentrations, suggesting that these changes result from a decrease in the oral clearance (CL) of AMG 487 (e.
2.Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme.
Henne KR1, Tran TB, VandenBrink BM, Rock DA, Aidasani DK, Subramanian R, Mason AK, Stresser DM, Teffera Y, Wong SG, Johnson MG, Chen X, Tonn GR, Wong BK. Drug Metab Dispos. 2012 Jul;40(7):1429-40. doi: 10.1124/dmd.112.045708. Epub 2012 Apr 19.
CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharmacokinetics in humans. Although in vitro activity loss assays failed to demonstrate CYP3A4 time-dependent inhibition (TDI) with AMG 487, its M2 phenol metabolite readily produced TDI when remaining activity was assessed using either midazolam or testosterone (K(I) = 0.73-0.74 μM, k(inact) = 0.088-0.099 min(-1)). TDI investigations using an IC(50) shift method successfully produced inhibition attributable to AMG 487, but only when preincubations were extended from 30 to 90 min. The shift magnitude was ∼3× for midazolam activity, but no shift was observed for testosterone activity. Subsequent partition ratio determinations conducted for M2 using recombinant CYP3A4 showed that inactivation was a relatively inefficient process (r = 36).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CXCR Products


VUF 11222
(CAS: 1414376-84-3)

High affinity non-peptide CXCR3 agonist (pKi = 7.2)

AMD 3465
(CAS: 185991-24-6)

AMD 3465,a N-pyridinylmethylene monocyclam, is a selective antagonist of CXCL12/CXCR4-mediated interactions including ligand binding and receptor activation. Wi...

CAS 155148-31-5 AMD 3100 octahydrochloride

AMD 3100 octahydrochloride
(CAS: 155148-31-5)

Highly selective CXCR4 chemokine receptor antagonist (IC50 values are 0.02 - 0.13 and > 25 μM for CXCR4 and all other chemokine receptors respectively)

CAS 333742-63-5 AZ 10397767

AZ 10397767
(CAS: 333742-63-5)

AZ 10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). It significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor mo...

ATI 2341
(CAS: 1337878-62-2)

CXCR4 allosteric agonist

KRH3955
(CAS: 1097732-62-1)

KRH3955 is a novel CXCR4 antagonist. It is an orally bioavailable compound. It inhibits SDF-1alpha-mediated chemotaxis and HIV-1 infection.

CAS 558447-26-0 AMD-070

AMD-070
(CAS: 558447-26-0)

Potent and selective antagonist of CXCR4 (with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay)

CAS 182498-32-4 SB225002

SB225002
(CAS: 182498-32-4)

Potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM

Chemical Structure

CAS 473719-41-4 (±)-AMG 487

Quick Inquiry

Verification code

Featured Items